CR9944A - Formulaciones con biodisponibilidad mejorada comprendiendo un derivado de esteroide y un glicerido poliglucosa - Google Patents

Formulaciones con biodisponibilidad mejorada comprendiendo un derivado de esteroide y un glicerido poliglucosa

Info

Publication number
CR9944A
CR9944A CR9944A CR9944A CR9944A CR 9944 A CR9944 A CR 9944A CR 9944 A CR9944 A CR 9944A CR 9944 A CR9944 A CR 9944A CR 9944 A CR9944 A CR 9944A
Authority
CR
Costa Rica
Prior art keywords
polyglucose
glyceride
formulations
understanding
steroid derivative
Prior art date
Application number
CR9944A
Other languages
English (en)
Inventor
Joseph Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CR9944A publication Critical patent/CR9944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Se ofrecen composiciones que comprenden un glicerido poliglucosa, como el GELUCIRE y un compuesto relacionado con esteroides.
CR9944A 2005-09-29 2008-04-28 Formulaciones con biodisponibilidad mejorada comprendiendo un derivado de esteroide y un glicerido poliglucosa CR9944A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72165305P 2005-09-29 2005-09-29

Publications (1)

Publication Number Publication Date
CR9944A true CR9944A (es) 2008-10-03

Family

ID=37602990

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9944A CR9944A (es) 2005-09-29 2008-04-28 Formulaciones con biodisponibilidad mejorada comprendiendo un derivado de esteroide y un glicerido poliglucosa

Country Status (13)

Country Link
US (1) US20090149434A1 (es)
EP (1) EP1940413A1 (es)
JP (1) JP2009510127A (es)
KR (1) KR20080055956A (es)
CN (1) CN101316595A (es)
AU (1) AU2006294449A1 (es)
CA (1) CA2623678A1 (es)
CR (1) CR9944A (es)
EA (1) EA200800974A1 (es)
IL (1) IL190405A0 (es)
NO (1) NO20081714L (es)
WO (1) WO2007038796A1 (es)
ZA (1) ZA200803177B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
MX2009006912A (es) * 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
AU2008290536B2 (en) * 2007-08-21 2012-02-09 Basilea Pharmaceutica Ag Antifungal composition
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
TW200944537A (en) * 2008-04-03 2009-11-01 Idenix Pharmaceuticals Inc Formulations comprising a phosphoindole compound and one or more second active agents
LT2419108T (lt) 2009-04-14 2016-12-27 Laboratoire Hra Pharma Kontracepcijos pagal poreikį būdas
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
BR112014029131B1 (pt) * 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) * 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
BR112019001225A2 (pt) * 2016-08-02 2019-04-30 Durect Corporation composições compreendendo sulfato de colesterol oxigenado e pelo menos um dentre polialquileno glicol, carboximetil celulose e polioxilglicerídeo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2253673C (en) * 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents

Also Published As

Publication number Publication date
EA200800974A1 (ru) 2008-10-30
IL190405A0 (en) 2008-11-03
EP1940413A1 (en) 2008-07-09
WO2007038796A1 (en) 2007-04-05
CA2623678A1 (en) 2007-04-05
NO20081714L (no) 2008-06-20
KR20080055956A (ko) 2008-06-19
CN101316595A (zh) 2008-12-03
JP2009510127A (ja) 2009-03-12
AU2006294449A1 (en) 2007-04-05
ZA200803177B (en) 2009-03-25
US20090149434A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
CR9944A (es) Formulaciones con biodisponibilidad mejorada comprendiendo un derivado de esteroide y un glicerido poliglucosa
CL2012000887A1 (es) Mezcla fungicida sinergica que comprende fluorocitosina y otros compuestos fungicos; composicion fungicida que comprende dicha mezcla y un adyuvante agricolamente aceptable o portador.
CL2008001879A1 (es) Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales.
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
AR056751A1 (es) Composiciones pesticidamente activas que tienen actividad mejorada
UY32659A (es) Pirazinilpirazoles
PA8667201A1 (es) Nuevos compuestos farmaceuticos
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
GT200500179BA (es) Mezclas sinergistas de agentes de antranilamida para el control de plagas de invertebrados
EA200802008A1 (ru) Фармацевтические композиции
EP1856237A4 (en) STABLE ORGANIC PEROXIDE COMPOSITIONS
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
SMAP200800041A (it) Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
UA107791C2 (en) Pesticidal compositions
GT200900027A (es) Compuestos organicos
EA201170703A1 (ru) Производные адамантилбензамида
AR050211A1 (es) Composiciones y metodos que usan interferencia de arn para el control de nematodos
MX2009004132A (es) Composiciones para contrarrestar el mal olor.
UY31688A1 (es) Plaguicidas
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
PA8792401A1 (es) Fenilendiaminas
GT200600121A (es) Novedosos derivados de triazolopirimidina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)